Automate Your Wheel Strategy on VSTM
With Tiblio's Option Bot, you can configure your own wheel strategy including VSTM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VSTM
- Rev/Share 0.0004
- Book/Share -0.5987
- PB -6.9485
- Debt/Equity -2.2436
- CurrentRatio 3.5009
- ROIC -1.3516
- MktCap 228588672.0
- FreeCF/Share -2.1255
- PFCF -1.9852
- PE -1.5137
- Debt/Assets 0.5525
- DivYield 0
- ROE 58.0644
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VSTM | Jefferies | -- | Buy | -- | $15 | April 10, 2025 |
| Reiterated | VSTM | H.C. Wainwright | -- | Buy | $7 | $10 | March 24, 2025 |
| Reiterated | VSTM | BTIG Research | -- | Buy | $13 | $20 | Dec. 31, 2024 |
| Initiation | VSTM | Guggenheim | -- | Buy | -- | $13 | Sept. 30, 2024 |
News
Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
Published: June 26, 2025 by: Seeking Alpha
Sentiment: Positive
Recent pipeline updates highlight promising new product candidates advancing to late-stage trials, strengthening my confidence in future growth. The company maintains a solid financial position, with strong cash reserves and prudent expense management supporting ongoing R&D initiatives. Key strengths include a diversified portfolio and robust clinical data, though regulatory risks and competition remain notable challenges.
Read More
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall.
Read More
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
Read More
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the front-line for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). As of April 25, 2025, patients in the dose level 1.
Read More
U.S. FDA approves Verastem's cancer therapy
Published: May 08, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer who have received prior treatment, the regulator said on Thursday.
Read More
Verastem Oncology Announces $75 million Private Placement
Published: April 25, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $24 million of shares of its common stock at a price of $7.00 per share and, in lieu of common stock to certain investors, $51 million of pre-funded warrants.
Read More
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
Read More
Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination
Published: April 10, 2025 by: Seeking Alpha
Sentiment: Positive
Verastem, Inc.'s priority review PDUFA date of avutometinib + defactinib for treatment of patients with recurrent LGSOC is expected June 30th of 2025; At this time, no FDA advisory committee to be held. The global Non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; KRAS G12C variant is the most common KRAS mutation, accounting for 13% of NSCLC cases. Data from phase 1/2 RAMP-203 study, using avutometinib + LUMAKRAS with or without defacinib to treat patients with KRAS G12C mutant NSCLC, is expected to be presented 2nd half of 2025.
Read More
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
About Verastem, Inc. (VSTM)
- IPO Date 2012-01-27
- Website https://www.verastem.com
- Industry Biotechnology
- CEO Daniel W. Paterson
- Employees 78